Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2007140534 - VEGF-A CROSS-REACTIVE ANTI- VEGF-B ANTIBODIES AS ANTAGONISTS OF VEGF-A AND VEGF-B SIGNALLING

Publication Number WO/2007/140534
Publication Date 13.12.2007
International Application No. PCT/AU2007/000799
International Filing Date 06.06.2007
IPC
C07K 16/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07K 7/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
C07K 7/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
CPC
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors ; ; against growth regulators
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • CSL LIMITED [AU]/[AU] (AllExceptUS)
  • NASH, Andrew [AU]/[AU] (UsOnly)
  • SCOTNEY, Pierre David [AU]/[AU] (UsOnly)
Inventors
  • NASH, Andrew
  • SCOTNEY, Pierre David
Agents
  • HUGHES, E., John, L.
Priority Data
200690311508.06.2006AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) VEGF-A CROSS-REACTIVE ANTI- VEGF-B ANTIBODIES AS ANTAGONISTS OF VEGF-A AND VEGF-B SIGNALLING
(FR) ANTICORPS VEGF-A ANTI-VEGF-B DOTÉS D'UNE RÉACTIVITÉ CROISÉE UTILISÉS COMME ANTAGONISTES DES SIGNAUX VEGF-A ET VEGF-B
Abstract
(EN)
The present invention relates generally to anti-VEGF-B antibodies and in particular to anti-VEGF-B antibodies which bind to VEGF-A and which antagonize VEGF-A and VEGF-B signaling. The antibodies of the present invention are useful in the treatment or prevention of VEGF-A- or VEGF-B-mediated diseases or conditions.
(FR)
La présente invention concerne d'une manière générale des anticorps anti-VEGF-B (facteur de croissance-B des cellules endothéliales vasculaires) et, en particulier, des anticorps anti-VEGF-B qui se lient au VEGF-A (facteur de croissance-A des cellules endothéliales vasculaires) et qui contrarient les signaux déclenchés par le VEGF-A et le VEGF-B. Les anticorps de la présente invention se révèlent utiles dans le traitement ou la prévention de maladies ou de signes cliniques induits par le VEGF-A ou le VEGF-B.
Latest bibliographic data on file with the International Bureau